Positive Health Online
Your Country
![[Image: http://www.abundanceandhealth.co.uk]](/img/original/BannerAvatar/2836.df7d2315253110ff5b3a566f94871f99.jpg "http://www.abundanceandhealth.co.uk")
![[Image: https://www.water-for-health.co.uk/]](/img/original/BannerAvatar/4046.12831f50177f8848ee87b8e94411d6b3.jpg "https://www.water-for-health.co.uk/")
![[Image: http://www.balens.co.uk]](/img/original/BannerAvatar/2148.50367fa908013fae0a7f1a171543ef92.jpg "http://www.balens.co.uk")
![[Image: http://www.drsgoodman.com/books-goodman/52-nutrition-and-cancer]](/img/original/BannerAvatar/1859.1296090fd8385e7ceff51c8011559097.jpg "http://www.drsgoodman.com/books-goodman/52-nutrition-and-cancer")
Research: FIORELLA and LORNA,
Listed in Issue 287
Abstract
FIORELLA and LORNA, 1 Universidad del Desarrollo-Clínica Alemana, Santiago, Chile; 2 Department of Neurology, Clínica Alemana, Santiago, Av Vitacura 5951, Vitacura, Santiago, Chile. lornag@gmail.com tested immunosuppressant agents as potential treatment for coronavirus 2019 (COVID-19) in patients with multiple sclerosis (MS).
Background
The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is a novel disease that has spread abruptly over the world, allowing the development of countermeasures an urgent global priority. It has been speculated that elder people and patient with comorbidities may be at risk of developing complications. On the other hand, it has been seen that immunosuppressed patients could develop a mild presentation of the disease. Based on this hypothesis, several immunosuppressant agents are currently being tested as potential treatment for coronavirus 2019 (COVID-19).
Methodology
The authors report a patient treated with alemtuzumab (Humanized monoclonal antibody against the lymphocyte and monocyte surface antigen CD52, which depletes B and T cells) (Thompson et al., 2018) for recurrent remittent multiple sclerosis (RRMS) who developed mild COVID-19.
Results
Despite complete B and T cell depletion, patient symptoms abated few days with no need for hospitalization due to COVID-19 and no clinical evidence of disease activation regarding her MS.
Conclusion
This report shows that MS patients with mild depletion of B and T cells can mount an antiviral response against COVID-19 and produce IgG. Copyright © 2020 Elsevier B.V. All rights reserved.
References
Celsi Fiorella 1 , Galleguillos Lorna 2 COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID . Mult Scler Relat Disord.;46:102447. Nov 2020 doi: 10.1016/j.msard.2020.102447. Epub 2020 Aug 10.
